HCLTECH
11.1.2024 14:05:00 CET | Business Wire | Press release
HCLTech, a leading global technology company, will join forces with key stakeholders from across the globe at the 54th Annual Meeting of the World Economic Forum (WEF) in Davos from Jan. 15–19, 2024. The company will contribute to deliberations on this year’s theme of “Rebuilding Trust” and discovering solutions with transparency, consistency and accountability.
HCLTech will be represented by its Chairperson Roshni Nadar Malhotra, CEO and Managing Director C Vijayakumar, Chief Technology Officer Kalyan Kumar; Chief Growth Officer for Europe and Africa, Ashish Kumar Gupta; President, Digital Foundation Services, Jagadeshwar Gattu; Global Head, Financial Services, Srinivasan Seshadri; Chief Marketing Officer Jill Kouri and Global Head, Sustainability, Santhosh Jayaram.
HCLTech will once again host guests at its pavilion at the iconic Promenade 66 which will be fully powered by locally produced green energy, underscoring the company’s commitment to a sustainable planet. In addition to its differentiated portfolio of services across digital, engineering, cloud, AI and software, HCLTech will showcase its award-winning sustainability solution, Net Intelligent Zero (NIO), at the pavilion with a live data feed.
This year, HCLSoftware makes its WEF debut with a dedicated lounge within the HCLTech pavilion. Chief Revenue Officer Rajiv Shesh and Chief Product Officer Kalyan Kumar will lead the HCLSoftware contingent that will showcase its cutting-edge software solutions that help enterprises navigate digital transformation.
HCLTech will participate in and host a series of panels and sessions on the future of technology, sustainability, diversity and inclusion in line with its brand purpose of bringing together the best of technology and its people to supercharge progress.
- The highlight this year will be the ‘Heroes of Progress’ reception on Jan. 17 to honor WEF Global Shapers who are making significant contributions to the fields of environment, women’s empowerment, art and sustainability.
- Roshni Nadar Malhotra, Chairperson, HCLTech is discussing the global water cycle and the potential of water as an enabler for SDGs on a panel on 'Out of Balance with Water' on Jan. 17, 15:00-15:45, Congress Center.
- Srinivasan Seshadri, Chief Growth Officer and Global Head, Financial Services, HCLTech, will lead an affiliate session on ‘Banking on trust through transformative tech’ on Jan. 16, 10:15-11:15 at Dome C, Ice Village.
- HCLTech is conducting broadcast sessions at its pavilion on Jan. 16, 17 and 18, 13:00–13:45. Dr. Saikat Chaudhuri, Innovation, Strategy and Engineering Professor, UC Berkeley will be moderating all three sessions with key industry leaders on: technology-led disruption, opportunities and impact; diversity-led progress for the future workforce; purpose-led sustainability agenda.
Additionally, HCL Group and Uplink, the open innovation platform of WEF, will announce the winners of this year’s Aquapreneur Challenge as part of their ongoing partnership.
To learn more about HCLTech@WEF 2024 visit World Economic Forum (WEF) 2024 at Davos | HCLTech.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240111423911/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 10:15:00 CEST | Press release
Doubtless combines industry-leading pet insurance with innovative care solutions, protecting more than 6 million pets across 10 global markets Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easie
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release
Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom